Published on 14 May 2020
Through a partnership with the CEA, BA Healthcare, young company from Rennes, is beginning the pre-series manufacture of monitoring devices to equip emergency and transport ventilators so that they can be used for resuscitation of Covid-19 patients
In order to address the current health crisis and the growing and urgent need to provide more artificial respirators, several manufacturers have been able to respond and mobilize their resources and production capacities. A significant number of ventilators dedicated to medical transport vehicles or emergency services have therefore been produced. However, in order to be used for optimal ventilation of Covid-19 patients, they had to be fitted with a continuous monitoring system for required pressure and flow rate.
In order to overcome this lack and improve patient management, the CEA LIST Carnot Institute, in collaboration with the CEA Frédéric Joliot Hospital Service, developed the CLEAR-M monitoring device.
On 10 April, two tests were carried out in hospital on test lungs, then in the medical intensive care unit at the Raymond Poincaré Hospital in Garches (AP-HP). The performance of CLEAR-M has been successfully validated by comparison with measurements from a reference ventilator.
On April 16, CLEAR-M was deployed at Garches Hospital to be evaluated on COVID-19 patients in recovery phase but still placed on artificial respiration. CLEAR-M was also deployed in the emergency ward of the Orsay hospital.
By agreement with the CEA, BA Healthcare was chosen to be the first industrial company to produce several thousand CLEAR-M units.
The production of twenty pre-series has started on the basis of the CEA prototypes. Marketing will begin shortly.
“We are proud to contribute, at our level, to the collective effort and the fight against Covid-19. Our teams are already fully mobilized and we look forward to starting series production. “said Samuel Pinault, Director of BA Healthcare.